Patent for Lilly's cancer drug Gemzar invalidated

A Michigan federal court ruled in favor of Sun Pharmaceuticals, invalidating Eli Lilly's method of use patent for its cancer drug Gemzar, which is not set to expire until 2013. Lilly still holds the compound patent for the drug, an injectible chemotherapy treatment for lung, breast, pancreatic and ovarian cancer that brought in $1.7 billion in worldwide sales in 2008. The pharma giant's shares fell 1.4 percent in premarket trading.

With the launch of Actavis' copycat in March, Lilly is already facing competition in Europe. The drugmaker saw worldwide Gemzar sales fall 17 percent to $721 million in H1 2009. In its statement, Lilly reassured investors that the court's decision does not make way for generic competition in the U.S. just yet: "Today's court decision does not allow for the immediate entry of generic gemcitabine in the U.S. market," Lilly's General Counsel said in a statement. "Gemzar's compound patent remains in force through 2010." The drugmaker, of course, said it plans to appeal the ruling. 

- here's the Eli Lilly release
- and the Bloomberg report
- more from Forbes

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Companies considering this avenue must think through potential implications despite the obvious attraction of early access for patients.

BD says a $1.2 billion investment in its pre-filled syringe business will add surge capacity needed to meet demand in future pandemics.

Ad Environment Matters for Message Receptivity